Grifols stock analysis
Grifols (0RDU) Share Price & Analysis
0RDU Stock Chart & Stats
- Day’s Range
- EUR 11.53 - EUR 11.67
- 52-Week Range
- EUR 8.45 - EUR 11.70
- Previous Close
- EUR 11.62
- Volume
- N/A
- Average Volume (3M)
- 46.91K
- Market Cap
- EUR 6.93B
- Enterprise Value
- EUR 17.71B
- Total Cash (Recent Filing)
- EUR 695.00M
- Total Debt (Recent Filing)
- EUR 9.24B
- Price to Earnings (P/E)
- 16.1
- Beta
- 0.99
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- 0.3
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.71%
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Margins
Revenue expansion alongside stronger EBIT and EBITDA margins indicates improving operating scale and execution. If maintained, this combination can support higher internal funding, reinforce the company’s position in plasma-derived therapies, and provide a stronger base for durable earnings growth.
Stronger Cash Generation
The recovery in operating cash flow and sustained positive free cash flow improves Grifols’ ability to fund investment, service obligations, and support its integrated operations. This provides greater financial resilience than the earlier period of weak or negative cash generation.
Vertically Integrated Plasma Model
Vertical integration connects plasma collection with manufacturing and distribution, giving Grifols control across key stages of its core business. That structure can support supply security, operating coordination, and retention of more value as demand for plasma-derived medicines develops.
Bears Say
Elevated Leverage
Historically high leverage can constrain capital allocation and leave less flexibility for investment or unexpected operating pressure. It also increases sensitivity to refinancing conditions and interest costs, making balance-sheet management an important limitation on otherwise improving operations.
Earnings Volatility
The sharp variation in net income shows that improved profitability has not yet demonstrated consistent durability across reporting periods. Continued earnings volatility could make planning, debt reduction, and reinvestment less predictable even as current operating margins are healthier.
Inconsistent Cash Conversion
Although recent cash generation is positive, the earlier negative free cash flow and subsequent slowing in its growth indicate that conversion remains uneven. This may limit the reliability of internally generated funds for debt reduction, reinvestment, and other long-term capital priorities.
0RDU FAQ
What was Grifols’s price range in the past 12 months?
What is Grifols’s market cap?
When is Grifols’s upcoming earnings report date?
How were Grifols’s earnings last quarter?
Is Grifols overvalued?
Does Grifols pay dividends?
What is Grifols’s EPS estimate?
How many shares outstanding does Grifols have?
What happened to Grifols’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Grifols?
What is the TipRanks Smart Score and how is it calculated?
Grifols Stock Smart Score
Company Description
Grifols
Grifols, S.A., a Spanish company established in 1940 and headquartered in Barcelona, specializes in the comprehensive process of acquiring, manufacturing, preparing, and distributing therapeutic products, with a primary focus on those derived from plasma. The company operates through several key divisions: Bioscience, Hospital, Diagnostic, and Bio Supplies, among others. The Bioscience division is dedicated to the research, development, production, and commercialization of plasma-derived medicines and other cutting-edge solutions. These are designed to treat individuals suffering from chronic, rare, widespread, and life-threatening medical conditions, with its product portfolio including immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division supplies a range of non-biological pharmaceutical products, clinical nutrition items, intravenous (IV) therapy solutions, and various medical devices and supplies. Grifols' Diagnostic division develops and markets advanced diagnostic tools that support healthcare professionals across the entire patient care continuum, from prevention and screening to accurate diagnosis, prognosis, and ongoing disease and treatment monitoring. Finally, the Bio Supplies division provides essential biological materials for life-science research, clinical trials, and the manufacturing of both pharmaceutical and diagnostic goods. Collectively, Grifols' offerings enable healthcare providers to effectively diagnose and treat a broad spectrum of medical conditions, such as hemophilia, various immune deficiencies, and infectious diseases. Its diverse client base includes public and private sector organizations, wholesalers, distributors, group purchasing organizations (GPOs), blood banks, hospitals, care institutions, and national health systems. Grifols also maintains a technology collaboration agreement with Mondragon.
- Sector
- General
- Industry
- Drug Manufacturers - General
- CEO
- Jose Ignacio Abia Buenache
- Employees
- 25,000
- Website
- www.grifols.com
- Address
- Parque Empresarial Can Sant Joan, Barcelona, CT, 08174, ES
Grifols (0RDU) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |












